Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2013-11-15 Board/Management Inform…
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details an amendment to a Restricted Stock Subscription Agreement for a CFO, which is a change related to compensatory arrangements of certain officers. This fits the category of Board/Management Information (MANG) as it involves management changes or amendments related to officers. The document is short (3081 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a report publication announcement or a regulatory filing of a different nature. Therefore, the best classification is MANG with high confidence.
2013-11-15 English
FORM 10-Q
Interim / Quarterly Report Q3 2013
2013-11-14 English
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a letter from the company's legal counsel responding to the SEC's comment letter regarding the company's previously filed Form 10-K for the fiscal year ended December 31, 2012. It discusses specific disclosures related to patent rights, license agreements, and collaboration agreements as requested by the SEC. The document references the 10-K filing and provides clarifications and proposed revisions to disclosures in that 10-K. It does not contain the 10-K report itself, nor does it include financial statements or substantive financial data. Instead, it is a regulatory correspondence responding to SEC comments on a previously filed annual report. According to the rules, such correspondence is classified as a Regulatory Filing (RNS) because it is a regulatory announcement and does not constitute the report itself.
2013-11-07 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text indicates the company issued a press release about unusual market activity in its stock price and confirms no material developments. The document is short (2528 characters) and primarily serves as an announcement of an event and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. This fits the definition of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories. It is not an Annual Report, Earnings Release, or any other detailed financial or management report. Therefore, the correct classification is Regulatory Filings (RNS).
2013-10-29 English
Regulatory Filings 2013
Regulatory Filings
2013-10-24 English
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a letter from the company's legal counsel responding to the SEC's comment letter regarding the company's previously filed Form 10-K for the fiscal year ended December 31, 2012. It addresses specific comments about disclosures in the 10-K, such as patent expiration dates and material terms of collaboration and license agreements. The document does not contain the 10-K report itself but is a correspondence related to the SEC review process. It is not a full financial report, earnings release, or any other report type but rather a regulatory correspondence. Therefore, it fits best under Regulatory Filings (RNS) as a response to SEC comments on a filing.
2013-10-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.